Skip to main content

Table 3 Validation of twenty one differentially expressed genes in CLL. Data from RNA seq analysis (n = 10), qRT-PCR of identical specimens (n = 10) and qRT-PCR from a test cohort (n = 22) of CLL specimens

From: Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens

CLL downregulated genes

Fold downregulation based on RNA-seq data (n =10)

Fold downregulation RNA-seq cohort (qRT-PCR data, n = 10)

Fold downregulation in test cohort qRT-PCR, n = 22)

 UACA, uveal autoantigen with coiled-coil domains and ankyrin repeats

44

9.8 ± 3.9

135 ± 3.7

 PTPRK, protein tyrosine and phosphatase, receptor type, K

24.2

*

*

 JUP, junction plakoglobin

13.4

44 ± 8.1

32 ± 5

 ITGA4, integrin, alpha 4 (CD49D, alpha 4 subunit of VLA-4 receptor)

10.3

6 ± 2.9

12.9 ± 2.5

 BANK1, B-cell scaffold protein with ankyrin repeats 1

7.2

1.23 ± 2

10.1 ± 1.86

 RHOB, ras homolog family member B

5.9

6.5 ± 2

1.97 ± 2.1

 Jam3, junctional adhesion molecule 3

5.59

3.5 ± 2.5

75.5 ± 3.6

 CD69, CD69 molecule

4.7

4.6 ± 1.7

1.07 ± 2.6 (upregulation)

 GRASP, (receptor for phosphoinositides 1)-associated scaffold protein

2.6

36.7 ± 6

9.8 ± 3.8

CLL upregulated genes

Fold downregulation based on RNA-seq data (n =10)

Fold downregulation RNA-seq cohort (qRT-PCR data, n = 10)

Fold downregulation in test cohort qRT-PCR, n = 22)

 THBS1, thrombospondin 1

528 ± 640

9.8 ± 15.8

12.9 ± 30.8

 TGFBR3, transforming growth factor, beta receptor III

373 ± 205

6.6 ± 1.6

30.5 ± 42

 GIMAP7, GTPase, IMAP family member 7

340 ± 305

34.2 ± 3.4

9.7 ± 7.7

 LYZ, lysozyme

41.8 ± 69

1.5 ± 5.6

10 ± 9.9

 PDE4a, phosphodiesterase 4A, cAMP-specific

26.5 ± 33.9

3 ± 3

4 ± 2.3

 MYL9, myosin, light chain 9, regulatory

24.9 ± 34

3.5 ± 3.4

8.7 ± 8.9

 RAPGEF 3, Rap guanine nucleotide exchange factor (GEF) 3

24 ± 14.7

17.1 ± 2.9

13.6 ± 11.3

 PIM1, pim-1 oncogene

13.9 ± 17

9.4 ± 7.9

6.75 ± 4.6

 RXRA, retinoid X receptor, alpha

13.2 ± 12.8

215 ± 196

9.4 ± 9

 LCK, lymphocyte specific protein tyrosine kinase

4 ± 2.4

3.2 ± 2.68

4.59 ± 2

 CLNK, cytokine-dependent hematopoietic cell linker

3.3 ± 1.8

26 ± 22

36.8 ± 45.2

 TGFbeta 1, transforming growth factor, beta 1

1.6 ± 1.1

1.07 ± 2.8

1.4 ± 2.7

  1. *PTPRK expression was not detected in normal B cells therefore fold change could not be calculated
  2. **downregulation of CD69 not validated in test cohort